Latent variable indirect response modeling of categorical endpoints representing change from baseline

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 40, Issue 1, 2013, Pages 81-91

  Hu, Chuanpu ^a   Xu, Zhenhua ^a   Mendelsohn, Alan M ^a   Zhou, Honghui ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Discrete variable; Golimumab; NONMEM; Population pharmacokinetic pharmacodynamic modeling; Rheumatoid arthritis

Indexed keywords

GOLIMUMAB; METHOTREXATE; PLACEBO;

ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; IC 50; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; STATISTICAL MODEL; STEADY STATE; STRUCTURAL EQUATION MODELING; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LOGISTIC MODELS; METHOTREXATE; MODELS, BIOLOGICAL; PLACEBO EFFECT;

EID: 84872897885     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-012-9288-7     Document Type: Article

References (18)

1. Dayneka NL, Garg V, Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21(4):457-478
2. Woo S, Pawaskar D, Jusko WJ (2009) Methods of utilizing baseline values for indirect response models. J Pharmacokinet Pharmacodyn 36(5):381-405
3. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V et al (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38(6):727-735
4. Mandema JW, Stanski DR (1996) Population pharmacodynamic model for ketorolac analgesia. Clin Pharmacol Ther 60(6):619-635
5. Hutmacher MM, Krishnaswami S, Kowalski KG (2008) Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients. J Pharmacokinet Pharmacodyn 35(2):139-157
6. Lacroix BD, Lovern MR, Stockis A, Sargentini-Maier ML, Karlsson MO, Friberg LE (2009) A pharmacodynamic Markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis. Clin Pharmacol Ther 86(4):387-395
7. Hu C, Xu Z, Rahman MU, Davis HM, Zhou H (2010) A latent variable approach for modeling categorical endpoints among patients with rheumatoid arthritis treated with golimumab plus methotrexate. J Pharmacokinet Pharmacodyn 37(4):309-321
8. Hutmacher MM, French JL (2011) Extending the latent variable model for extra correlated longitudinal dichotomous responses. J Pharmacokinet Pharmacodyn 38(6):833-859
9. Hu C, Szapary PO, Yeilding N, Zhou H (2011) Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasis. J Pharmacokinet Pharmacodyn 38(2):237-260
10. Hu C, Yeilding N, Davis HM, Zhou H (2011) Bounded outcome score modeling: application to treating psoriasis with ustekinumab. J Pharmacokinet Pharmacodyn 38(4):497-517
11. Simponi [package insert] (2011) Janssen Biotech, Inc. Horsham, PA
12. Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, Han J, Taylor P (2010) Golimumab, a new human anti-tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: forty-eight-week efficacy and safety results of a phase III, randomized, double-blind, placebo-controlled study. Arthritis Rheum 62(4):917-928
13. Weinblatt ME, Bingham CO III, Mendelsohn AM, Kim L, Mack M, Lu J, Baker D, Westhovens R (2012) Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis. doi: 10.1136/annrheumdis- 2012-201411
14. Hu C, Zhou H (2008) An improved approach for confirmatory phase III population pharmacokinetic analysis. J Clin Pharmacol 48(7):812-822
15. Cox DR, Hinkley DV (1979) Theoretical statistics. Chapman & Hall/CRC Press LLC, Boca Raton
16. Karlsson MO, Holford N (2008) A tutorial on visual predictive checks. Population Approach Group in Europe. Abstract 1434. http://www.page-meeting.org/ ?abstract=1434. Accessed 20 Dec 2012
17. Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel BA, Doyle MK, Visvanathan S, Xu W, Rahman MU (2009) Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 60(8):2272-2283
18. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, Pazdur J, Bae SC, Palmer W, Zrubek J, Wiekowski M, Visvanathan S, Wu Z, Rahman MU (2009) Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 68(6):789-796